A Phase I, 2-panel, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and CYP3A Inhibitors, Erythromycin and Darunavir/Ritonavir (DRV/r).

Trial Profile

A Phase I, 2-panel, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and CYP3A Inhibitors, Erythromycin and Darunavir/Ritonavir (DRV/r).

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2011

At a glance

  • Drugs Darunavir; Erythromycin; Ritonavir; Simeprevir
  • Indications Bacterial infections; Hepatitis C; HIV infections; Infections
  • Focus Pharmacokinetics
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 31 Oct 2011 Actual end date Aug 2011 added as reported by ClinicalTrials.gov.
    • 31 Oct 2011 Actual initiation date changed from Apr 2011 to Mar 2011 as reported by ClinicalTrials.gov.
    • 31 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top